RS
VNDA icon

R Squared’s Vanda Pharmaceuticals VNDA Stock Holding History

R Squared’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-17,556
Closed -$82.9K – 714
2025
Q2 		$82.9K Buy
+17,556
New +$76.8K 0.05% 362
2025
Q1 		– Sell
-140
Closed -$671 – 1491
2024
Q4 		$671 Buy
+140
New +$672 ﹤0.01% 1528

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

R Squared's VNDA Position: Q3 2025 in Review

R Squared sold out of Vanda Pharmaceuticals (VNDA) in Q3 2025, closing a stake of 17,556 shares — an estimated $82.9K sold.

R Squared first reported a position in VNDA in Q4 2024 and held it in 2 quarters. The position peaked at $82.9K in Q2 2025. 150 funds tracked by Wall St. Rank hold VNDA as of Q3 2025.

  • R Squared reported no remaining Vanda Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • R Squared sold 17,556 Vanda Pharmaceuticals shares in Q3 2025, an estimated $82.9K.
  • R Squared first reported a position in Vanda Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • R Squared's Vanda Pharmaceuticals position peaked at $82.9K in Q2 2025.
  • 150 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2025.

Based on R Squared's 13F filing for Q3 2025, filed 12 Nov 2025.